|
Recent Developments |
|
02-MAY-14
Wintac announced that the company has received the US FDA approval for the manufacturing plant (manufacture of pharmaceutical formulations - sterile injections and ophthalmic products) at Nelamangala, Bangalore.
23-APR-10
Wintac announced that it has received formal approval for the ANDA from US FDA authorities for Ondansetron Hydrochloride 20 ml Injection.
03-DEC-09
Wintac today announced that its manufacturing plant at Nelamangal... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 30-Sep-2016(6) | 31-Mar-2016(12) | 31-Mar-2015(12) | | Net sales | 91.73 | 180.98 | 290.77 | | Other Income | 4.18 | 1.86 | 1.37 | | Total Income | 95.91 | 182.84 | 292.14 | | Cost of goods sold | 186.69 | 293.69 | 314.37 | | OPBDIT | -90.78 | -110.85 | -22.23 | | PAT | -106.64 | -151.33 | -61.55 | | Gross Block | - | - | - | | Equity capital | 100.24 | 100.24 | 100.24 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | -94.7 | -60.6 | -7.6 | | Net margin (% of OI) | -111.2 | -82.8 | -21.1 |
|
|
Detailed Financials
|
|
|
|
|
